{"id":"W4224252082","doi":"10.1016/j.eclinm.2022.101409","title":"Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)","year":2022,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"Biomedical Advanced Research and Development Authority; Genentech; H. Lundbeck A/S; Swedish Orphan Biovitrum; Novo Nordisk; Lundbeckfonden; Gilead Sciences; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; Erik og Susanna Olesens Almenvelgørende Fond; LivaNova; Pfizer; Bristol-Myers Squibb; AstraZeneca; Bayer HealthCare; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Tocilizumab; Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Pneumonia; Betacoronavirus; Antibody; Virology; Viral pneumonia; Intensive care medicine; Internal medicine; Immunology; Outbreak; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003279074,0.001251261,0.003380358,0.0003959485,0.0004438734,0.001424779,0.0008174322,0.001805668,0.006978904],"category_scores_gemma":[0.003903811,0.0005811352,0.003129518,0.0006383915,0.000995458,0.0008051248,0.0005076095,0.002297212,0.0005882414],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001152416,"about_ca_system_score_gemma":0.001423444,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001849737,"about_ca_topic_score_gemma":0.00325371,"domain_scores_codex":[0.9981889,0.001083175,0.000194031,0.0002460623,0.0001199429,0.0001678057],"domain_scores_gemma":[0.9981736,0.0004947647,0.0006339765,0.0001200182,0.0001590865,0.000418574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9897328,0.0009623,0.0004308515,0.0011255,0.001288415,0.00001843422,0.00002525187,0.00007334453,0.0006804077,0.00004066893,0.0004243175,0.005197669],"study_design_scores_gemma":[0.9808953,0.01591387,0.00166514,0.00006624371,0.0009023624,0.00001760685,0.00001054993,0.00009704396,0.00007992292,0.00004555487,0.0002982686,0.000008053322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.957383,0.02718231,0.0006138821,0.001403121,0.001255051,0.007328419,0.002488662,0.0001148029,0.002230623],"genre_scores_gemma":[0.9740238,0.009404446,0.001212358,0.001368441,0.0009750287,0.008871898,0.001761015,0.00001902064,0.002364098],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006978904,"threshold_uncertainty_score":0.02334672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02606144175745058,"score_gpt":0.3980368495102848,"score_spread":0.3719754077528343,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}